RBC Capital maintains Outperform rating on Xencor, $43 price target

What happened

RBC Capital kept its Outperform rating on Xencor and set a $43 price target, implying 47.4% upside from the October 26 close of $29.18. RBC cited strong XmAb819 kidney cancer trial data and Xencor's drug pipeline.

Confirmed

Global impact / market context

A higher price target signals analysts expect more value from Xencor's drug pipeline. The 45.5% response rate in the XmAb819 trial may support later testing, while advancing its own assets instead of partnering could keep more future revenue and profit in-house.

Analyst inference

Xencor shares closed at $29.18 on October 26, well below the $43 target. The rating reflects analyst expectations rather than company guidance. The note points to clinical data and pipeline progress as reasons investors might expect growth in oncology and autoimmune treatments.

Analyst inference

What to watch

1. Watch future XmAb819 trial updates after the 45.5% overall response rate reported in the dose escalation study for late-line renal cell carcinoma, which means kidney cancer treated after earlier therapies fail. Confirmed
2. RBC Capital proposes that Xencor keep advancing its own drug assets rather than seeking partnerships, a strategy the note says could enhance long-term value creation, meaning more future revenue stays with the company. Proposed
3. Track whether later XmAb819 results confirm the early efficacy signal, since the analyst view assumes the drug can outperform existing late-line kidney cancer therapies, which would support revenue potential and the $43 target. Analyst inference

Evidence

• Original source link unavailable